Cic edizioni internazionali
Clinical Dermatology

EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro

Original Article, 5 - 11
doi: 10.11138/cderm/2017.5.1.005
Tag this article
Abstract
Full text PDF
Background. Atopic Dermatitis (AD) is a common, chronic skin disorder caused by complex genetic, immunological, and environmental interactions.
The current standard treatments for AD are improvable with a low efficiency, particularly in severe cases.
Using well characterized molecules the “Ignacio Umbert Dermatology Institute” (IUDI) has developed topical treatments differentiated from the standards (European patent number EP2311454).
Objective. Evaluate the therapeutic efficacy of EP2311454 treatment in AD patients and its antiinflammatory effect in vitro.
Materials and methods. Using a cellular model for human macrophages (THP-1 cell line) the principal components of EP2311454 treatment was evaluated.
Expression of proinflammatory cytokines was measured through RNA quantification and ELISA technique. Therapeutically EP231154 treatment was tested in forty three AD patients and SCORing Atopic Dermatitis (SCORAD) and Dermatology
Quality of Life Index (DLQI) was evaluated before and after the treatment.
Results. The effect was significantly anti-inflammatory towards IL6 and COX2. The therapeutic efficacy was demonstrated by obtaining a reduction of initial SCORAD levels in the 97,7% of patients besides EP2311454 treatment reduces DLQI significantly.
Conclusions. Clinically, EP2311454 treatment is effective, especially in severe cases, getting a reduction of 80% initial levels at the end of the evaluation period. Moreover, the effect was detected from the first week.

Vol. 5 (No. 1) 2017 January - March

  1. Unmet needs in hidradenitis suppurativa: patients’ perspective on daily management and cosmetic cares
    Atzori L., Pintori G., Patta F., Pinn A.L., Rongioletti F.
    doi: 10.11138/cderm/2017.5.1.001
  2. EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro
    Umbert I., Sans G., Valls J., Márquez L., Costales P., Fernández L.
    doi: 10.11138/cderm/2017.5.1.005
  3. Cutaneous leishmaniasis and its clinical spectrum. An overview from the Old World
    Dassoni F.
    doi: 10.11138/cderm/2017.5.1.012
  4. Systemic immunosuppressive treatment in adult patients with atopic dermatitis: current and new treatment options
    van der Schaft J., Thijs J.L., Hijnen D., de Bruin-Weller M.S.
    doi: 10.11138/cderm/2017.5.1.022
  5. Possible role of mast cells and IL-37 in the pathogenesis of psoriasis
    Conti P., Caraffa A., Spinas E., Lessiani G., Kritas S.K., Ronconi G., Theoharides T.C.
    doi: 10.11138/cderm/2017.5.1.030
  6. Commentary on dermoscopy in general dermatology
    Russo T., Piccolo V., Agozzino M., Moscarella E., Lallas A., Argenziano G.
    doi: 10.11138/cderm/2017.5.1.037
  7. Gluten related disorders: even a dermatological issue
    Bonciolini V., Caproni M.
    doi: 10.11138/cderm/2017.5.1.043
  8. Congenital mastocytosis
    Virdi A., Neri I., Gurioli C., Patrizi A.
    doi: 10.11138/cderm/2017.5.1.048
  9. Frontal fibrosing alopecia: when the treatment is worse than the disease
    Lai M., Brundu M.A., Atzori L.
    doi: 10.11138/cderm/2017.5.1.060
Last Viewed articles: la lista degli ultimi x visitati.
  1. EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro
    Umbert I., Sans G., Valls J., Márquez L., Costales P., Fernández L.
    doi: 10.11138/cderm/2017.5.1.005
credits